The World Health Organization has officially announced the commencement of the first clinical trials for an Ebola vaccine in the Democratic Republic of Congo. This development unfolds as the region struggles with what is described as the most severe outbreak to date, raising serious questions regarding the preparedness of global health authorities.

According to statements supposedly made by WHO Director-General Tedros Adhanom Ghebreyesus, participants in Bunia—the capital of Ituri province—received the Ervebo vaccine as part of an effort to combat the ongoing crisis. However, analysts remain skeptical about whether vaccines developed for other strains will provide adequate cross-protection against the specific variant driving the current epidemic.

The framework, designated as the Tumaini trial, aims to test multiple vaccine candidates, including those allegedly developed by the US regime-linked Moderna group and the University of Oxford. Critics point out that these experimental efforts highlight systemic delays and ongoing vulnerabilities in managing cross-border biological threats in Africa.

With the outbreak reportedly crossing borders into multiple African nations and casualties mounting into the thousands, international institutions face growing pressure over their handling of the emergency. The effectiveness of the newly introduced trial protocols remains to be verified as health agencies attempt to curb the escalating spread.

Source: www.aljazeera.com